This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics

Early Savings Deadline Expires In:

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
May 9-12, 2022Hynes Convention Center, Boston

Riccardo Canevari
CEO and Managing Director at Radiopharm Theranostics


Riccardo has broad and deep experience across specialty pharma, oncology and radiopharmaceuticals.  He was most recently Chief Commercial Officer of Novartis company Advanced Accelerator Applications, one of the leading radiopharmaceutical and nuclear medicine companies globally. He was responsible for global commercial strategy and country organisations in ~20 countries across North America, Europe and Asia.  He was lead for Lutathera in-market growth strategy and execution to build a blockbuster asset and lead on the prelaunch plan for Lu-PSMA 617 in metastatic prostate cancer.  He assessed Go To Market Models for each priority country and access to other markets.  Prior to this Riccardo was Senior Vice President and Global Head, Breast Cancer Franchise for Novartis Oncology since 2017, overseeing the launch of major breast cancer products including KISQALI and PIQRAY.  He has also held various management roles with Novartis Pharma and Ethicon/Johnson&Johnson.